126 related articles for article (PubMed ID: 33336792)
1. DECC (dexamethasone, etoposide, chlorambucil, lomustine) as an oral chemotherapy regimen in relapsed and refractory diffuse large B-cell lymphoma.
Maddox JM; Horan M; Tafesh L; Shrubsole C; Osborne W
Br J Haematol; 2021 Feb; 192(3):e92-e94. PubMed ID: 33336792
[No Abstract] [Full Text] [Related]
2. The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control.
Proctor SJ; Lennard AL; Jackson GH; Jones GL; Lewis J; Wilkinson J; White J; Sieniawski M; McKay P; Culligan D; Lucraft HH
Ann Oncol; 2010 Feb; 21(2):426-428. PubMed ID: 19901016
[No Abstract] [Full Text] [Related]
3. Primary treatment of low-grade non-Hodgkin's lymphoma using an all oral anthracycline-containing regimen, chlorambucil, idarubicin, dexamethasone (CID)--a phase II study.
Taylor PR; Jackson GH; Galloway MJ; Soukop M; Tinegate H; Angus B; Proctor SJ
Cancer Chemother Pharmacol; 2000; 46(1):63-8. PubMed ID: 10912580
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
Ivanov V; Tabouret E; Chuto G; Chetaille B; Fezoui H; Coso D; Rey J; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Blaise D; Bouabdallah R
Leuk Lymphoma; 2010 Sep; 51(9):1758-60. PubMed ID: 20629527
[No Abstract] [Full Text] [Related]
5. Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.
Puig N; Wang L; Seshadri T; al-Farsi K; Keating A; Crump M; Kuruvilla J
Leuk Lymphoma; 2013 Mar; 54(3):507-13. PubMed ID: 22897731
[TBL] [Abstract][Full Text] [Related]
6. Lomustine, etoposide, methotrexate and prednisone (LEMP) therapy for relapsed and refractory non-Hodgkin's lymphoma.
Dorigo A; Mansberg R; Kwan YL
Eur J Haematol; 1993 Jan; 50(1):37-40. PubMed ID: 8436213
[TBL] [Abstract][Full Text] [Related]
7. The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.
Cox MC; Pelliccia S; Marcheselli L; Battistini R; Arcari A; Borza PA; Patti C; Casaroli I; di Landro F; Di Napoli A; Fabbri F; Caridi M; Tafuri A; Bocci G; Musuraca G
Invest New Drugs; 2019 Jun; 37(3):548-558. PubMed ID: 31028663
[TBL] [Abstract][Full Text] [Related]
8. A retrospective multicentre study of COCKLE, an oral chemotherapy regimen, as palliative treatment for high grade lymphoma.
Maybury B; Kimpton G; Otton S
Br J Haematol; 2019 May; 185(4):803-806. PubMed ID: 30407622
[No Abstract] [Full Text] [Related]
9. UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan.
Yamasaki S; Tanimoto K; Kohno K; Kadowaki M; Takase K; Kondo S; Kubota A; Takeshita M; Okamura S
Ann Hematol; 2015 Jan; 94(1):65-9. PubMed ID: 25055799
[TBL] [Abstract][Full Text] [Related]
10. Ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide therapy for central nervous system recurrence of diffuse large B-cell lymphoma in patients with poor performance status: a pilot study.
Miwa A; Sekiguchi N; Tanimura A; Homma C; Shikai T; Takezako Y; Yamagata N; Takezako N
Leuk Lymphoma; 2011 Oct; 52(10):1898-903. PubMed ID: 21649542
[TBL] [Abstract][Full Text] [Related]
11. Treatment with cyclophosphamide, vindesine, cytarabine, dexamethasone and bleomycin in patients with relapsed/refractory diffuse large B-cell lymphoma.
Li M; Li Y; Yin Q; Mi R; Chen L; Du J; Wei X
Leuk Lymphoma; 2014 Jul; 55(7):1578-83. PubMed ID: 24070424
[TBL] [Abstract][Full Text] [Related]
12. An effective oral combination in advanced relapsed Hodgkin's disease prednisolone, etoposide, chlorambucil and CCNU.
Lennard AL; Carey PJ; Jackson GH; Proctor SJ
Cancer Chemother Pharmacol; 1990; 26(4):301-5. PubMed ID: 2369796
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.
Elstrom RL; Andemariam B; Martin P; Ruan J; Shore TB; Coleman M; Leonard JP; Furman RR
Leuk Lymphoma; 2012 Aug; 53(8):1469-73. PubMed ID: 22263572
[TBL] [Abstract][Full Text] [Related]
14. [Clinical Efficacy Comparison of Different Second Line Salvage Chemotherapy Regimens for the Treatment of Elderly Patients with Relapsed and Refractory Diffuse Large B Cell Lymphoma].
Liu YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):448-51. PubMed ID: 27151008
[TBL] [Abstract][Full Text] [Related]
15. High-dose chlorambucil and dexamethasone for relapsed non-Hodgkin's lymphomas.
Joseph G; Hadley T; Djulbegovic B; Hamm J; Seeger J; Blumenreich M; Woodcock T
Am J Clin Oncol; 1993 Aug; 16(4):319-22. PubMed ID: 8328409
[TBL] [Abstract][Full Text] [Related]
16. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma.
Bertè R; Vallisa D; Civardi G; Moroni CF; Lazzaro A; Cavanna L
Acta Haematol; 2001; 106(3):141-2. PubMed ID: 11713384
[No Abstract] [Full Text] [Related]
18. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
20. Prednisolone, cytosine arabinoside, lomustine (CCNU), etoposide and thioguanine (PACET) combination chemotherapy for relapsed or refractory non-Hodgkin lymphoma.
Sweetenham JW; McKendrick JJ; Mead GM; Whitehouse JM
Eur J Cancer; 1993; 29A(2):190-2. PubMed ID: 8422281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
